Reshaping Dyslipidaemia Treatment with Bempedoic Acid—A Narrative Review
Dyslipidaemia is one of the main causes of atherosclerotic cardiovascular disease (ASCVD) worldwide. Although statins remain the cornerstone of lipid-lowering therapy, many patients do not achieve optimal target levels of low-density lipoprotein cholesterol (LDL-C) due to intolerance or inadequate r...
Saved in:
| Main Authors: | Dominik Strikic, Zvonimir Begic, Ivana Radman, Fran Zlopasa, Jana Mateljic, Ivica Zec, Marina Titlic, Ana Marija Sliskovic, Ivan Pecin, Zeljko Reiner, Iveta Mercep |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/6/1460 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Triple Non-Statin Therapy with Ezetimibe, Inclisiran, and Bempedoic Acid in Patients with Genetically Confirmed Statin-Induced Rhabdomyolysis: A Dual Case Report
by: Jozef Dodulík, et al.
Published: (2025-05-01) -
Bempedoic Acid for Prevention of Cardiovascular Events in People With Obesity: A CLEAR Outcomes Subset Analysis
by: Harold E. Bays, et al.
Published: (2025-02-01) -
The Pathogenetic Basis of the Action of Bempedoic Acid
by: A. S. Petrosyan, et al.
Published: (2023-01-01) -
Bempedoic Acid in Patients with Dyslipidemia: A Systematic Review and Meta-Analysis
by: Shambo S. Samajdar, et al.
Published: (2025-05-01) -
Addition of Bempedoic Acid to Statin–Ezetimibe versus Statin Titration in Patients with High Cardiovascular Risk: A Single-Centre Prospective Study
by: Giuseppe Marazzi, et al.
Published: (2024-09-01)